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Introduction {#sec001}
============

The fact that melanomas can present with varied morphologies and biologic behaviors including differences in rate of growth, anatomical location and propensity to metastasize has been known for quite some time. Initial attempts at subtyping melanomas based on their clinical and histopathology characteristics lead to the classification of these tumors into superficial spreading, nodular, acro-lentiginous, and lentigo maligna, among others. Some have tried to simplify this classification based on the degree of UV exposure into melanomas on chronic sun damaged skin, melanomas on intermittent sun exposed skin and melanomas on UV protected sites \[[@pone.0179745.ref001]\]. However, evidence is now starting to emerge that the underpinnings responsible for the morphology and biology of melanoma may primarily be due to their molecular profile (gene expression profile) \[[@pone.0179745.ref002]\]. It has been shown that approximately 50% of melanomas have a *BRAF*V600 mutation \[[@pone.0179745.ref003]\]. Few recent studies have sought to correlate *BRAF* mutational status with features observed via non-invasive evaluation techniques, such as dermoscopy \[[@pone.0179745.ref004],[@pone.0179745.ref005],[@pone.0179745.ref006]\]. Researches have noted that *BRAF* mutated melanomas tend to be of the superficial spreading type and often reveal peppering on dermoscopy \[[@pone.0179745.ref005]\]. Ruini et al. used Reflectance Confocal Microscopy (RCM) to evaluate 8 melanomas and suggested that RCM may provide more specific information on the cytoarchitectural structure of *BRAF* mutated melanomas \[[@pone.0179745.ref007]\]. Our present study was undertaken to determine whether the RCM characteristics of the *BRAF* V600E mutated melanomas differ from the *BRAF* wild type melanomas.

Material and methods {#sec002}
====================

This study was approved by the Institutional Review Board of A C Camargo Cancer Center, São Paulo, Brazil and it was registered under no. 1685/12.

Subjects {#sec003}
--------

This retrospective cohort study included 32 consecutively diagnosed melanomas; all of which were imaged with RCM prior to biopsy. Only thin melanomas were included as RCM is not able to reach deeper skin layers. Each of the 32 melanomas came from a different patient and all cases were diagnosed between 2011 and 2013. Informed consent was not necessary because the data were analyzed anonymously.

Routine histopathology {#sec004}
----------------------

The histopathology slides were stained with hematoxylin-eosin and the pathologist (C.P.) was required to comment on the following parameters according to the Pathology Department's protocol: histological subtype, growth pattern, Breslow thickness, Clark\'s level, peritumoral inflammatory infiltrate, intratumoral inflammatory infiltrate, regression, lymphatic invasion, vascular invasion, perineural invasion, existence of associated nevus, microscopic satellites, and mitotic rate. Histopathology images were obtained of all cases using ScanScope Digital Slide Scanner (Aperio, Vista, CA, USA).

*BRAF* immunohistochemistry {#sec005}
---------------------------

The archived specimens were retrieved and processed by deparaffinization followed by antigen retrieval and dilution using the anti-VE1 antibody, which was performed on Ventana Benchmark XT immunostainer (Roche Diagnostics, Burges Hill---UK), according to specified standard protocol. OptiView DAB IHC Detection Kit (Roche, Burges Hill-UK) was used to detect V600E *BRAF* protein expression. The slides were stained with anti-V600E *BRAF* (VE1) Mouse Monoclonal Primary Antibody (Roche, Burges Hill-UK). Positive control with *BRAF* V600E mutated colorectal adenocarcinoma was used for procedure standardization. The omission of this antibody in tissue known to be positive for the *BRAF* V600E mutation served as the negative control. All immunohistochemistry stained slides were evaluated by the same pathologist (PCA). Immunostaining was interpreted as positive or negative according to criteria proposed by Capper et al. \[[@pone.0179745.ref008]\] and Long et al. \[[@pone.0179745.ref009]\], VE1 antibody staining was considered positive if tumor cells showed unambiguous cytoplasmic staining. The staining reaction was considered negative if there was no evidence of staining or if there was only weak, focal staining of isolated cells.

Molecular biology testing is still the gold standard method for *BRAF* V600E status assessment. However, a plenty of studies have shown that VE1 antibody staining is a less expensive approach to rapidly evaluate the *BRAF* V600E mutation in melanomas \[[@pone.0179745.ref010]\].

All study lesions proved to be relatively thin invasive melanomas or *in situ* melanomas. Hence the degree of *BRAF* staining in the *BRAF* mutated tumors was mostly weak to moderate and distributed focally or multifocally ([Fig 1](#pone.0179745.g001){ref-type="fig"}).

![Tumor tissues with hematoxylin-eosin staining and with immunohistochemistry reaction for anti-VE1 antibody.\
(A) Histopathological features of *in situ* superficial spreading melanoma, exhibiting mainly scattered melanocytes along the basal layer and only few pagetoid cells spreading in the epidermis (H&E staining, original magnification 400x) (B) *BRAF* V600E IHC negative case characterized by complete lack of tumor cell immunostaining (original magnification 400x)---A and B corresponding to the case in [Fig 2](#pone.0179745.g002){ref-type="fig"} (2A). (C) Histopathological features of superficial spreading melanoma, 1 mm in Breslow thickness showing a predominantly nested pattern of large intraepidermal and junctional nests (arrows) (H&E staining, original magnification 400x). (D) *BRAF* V600E cytoplasmic immunostaining positive (original magnification 200x)---C and D corresponding to the case in [Fig 2D](#pone.0179745.g002){ref-type="fig"}.](pone.0179745.g001){#pone.0179745.g001}

Instruments {#sec006}
-----------

RCM images were acquired using the near-infrared reflectance confocal laser microscope (Vivascope 1500; Caliber I.D., Rochester, NY, USA). The RCM scanning technique and the acquisition of RCM images was the same as published by Pellacani et al. \[[@pone.0179745.ref011]\]. RCM "mosaic images", ranging in size from 4x4 to 8x8 mm, were captured in all cases (\"Vivablock\"). A minimum of three mosaics was obtained for each lesion with at least one mosaic acquired at the superficial epidermal layer, one at dermal-epidermal junction (DEJ) and one at the papillary dermis. In addition, focal areas of interest were imaged via the "stack" method, which captures images of the area of interest by acquiring sequential images from the stratum corneum up to papillary dermis.

Parameter evaluation {#sec007}
--------------------

RCM: Two dermatologists with experience in reading RCM images (TBJC and RGG) independently evaluated all of the RCM images blinded to both dermoscopic and histopathological features. The findings were categorized in a binary fashion for the following parameters \[[@pone.0179745.ref012],[@pone.0179745.ref013],[@pone.0179745.ref014]\].

1.  Epidermal layer: presence or absence of atypical honeycomb pattern, atypical cobblestone pattern, pagetoid pattern and hyporreflective cells. If within any 1x1mm field of view there were more then 10 pagetoid cells per mm^2^ we considered this parameter to be present and if ≤ 10 pagetoid cells it was considered as absent. Hyporreflective cells were considered present if more than 5 cells were seen in any high power field (1x1).

2.  Dermal-epidermal junction (DEJ): presence or absence of junctional nests, edged papillae, non-edged papillae, non-visible papillae, sheet-like structures, mitochondria-like structures, meshwork pattern and junctional thickening (enlargement of the inter-papillary spaces by bright sparse cells or in aggregates \<5 cells).

3.  Superficial dermis: presence or absence of bright dots, sparse plump cells, aggregated plump cells, reticulated collagen, and collagen in bundles.

Statistical analysis {#sec008}
--------------------

The results were tabulated and the frequency distributions, standard deviations, and range of measurements calculated. The Mann -Whitney test was used to compare the mean age as a function of *BRAF* V600E expression. The Fisher\'s Exact Test was used to evaluate the association between the expression of *BRAF* V600E and the presence or absence of: growth phase (radial or vertical), hyporreflective cells, epidermal nests, dermal-epidermal junction (DEJ) nests, edged papillae, nonedged papillae, junctional thickening, meshwork pattern and bright dots.

Multiple logistic regression was employed to identify the independent RCM factors predictive of positive *BRAF* V600E mutation status. All RCM variables seen in *BRAF* V600E mutated and *BRAF* wild type melanomas were compared and any variable that was found to be different between these two groups, with p value of less than 0.20, in univariate analysis were selected for a stepwise forward selection model and only variables with a p value less than or equal to 0.05 remained in the final multiple logistic model. The predictive value of the final model was assessed by calculating the area under the ROC curve (AUC).

Microsoft Excel 2007 ([www.microsoft.com](http://www.microsoft.com/)) and the IBM SPSS version 22.0.0.0 were used for all analyses.

Results {#sec009}
=======

A total of 32 melanomas from 16 women and 16 men with ages ranging between 28 and 85 years were evaluated. Four melanomas (12.5%) were located on the head and neck area, 13 (40.6%) on the torso, 12 (37.5%) on the arm and 3 on the leg ([Table 1](#pone.0179745.t001){ref-type="table"}).

10.1371/journal.pone.0179745.t001

###### Clinical variables and *BRAF* V600E mutation.

![](pone.0179745.t001){#pone.0179745.t001g}

                                                                                *BRAF* V600E                      
  ------------------------------------------------------------- --------------- -------------- ------------- ---- ----------
  Gender                                                        Male            13 (56.5%)     3 (33.3%)     16   0.4
  Female                                                        10 (43.4%)      6 (66.7%)      16                 
  **[\*](#t001fn001){ref-type="table-fn"}Age**                  Mean (SD)       58.6 (14.3)    58.1 (14.6)        **0.02**
  **[\*](#t001fn001){ref-type="table-fn"}Age \< 50years old**   Mean (SD)       56.7 (14.1)    58.1 (14.6)        **0.03**
  Topography                                                    Head and neck   3 (75.0%)      1 (25.0%)     4    0.9
  Superior limb                                                 8 (66.7%)       4 (33.3%)      12                 
  Trunk                                                         10 (76.9%)      3 (23.1%)      13                 
  Inferior limb                                                 2 (66.7%)       1(33.3%)       3                  

\*Mann Whitney Test

a\. Negative: absence of staining

b\. Positive: any positive staining (focal or multifocal).

Histopathology variables were assessed and are summarized in [Table 2](#pone.0179745.t002){ref-type="table"}.

10.1371/journal.pone.0179745.t002

###### Histological variables and *BRAF* V600E mutation.

![](pone.0179745.t002){#pone.0179745.t002g}

                                                                     *BRAF* V600E                      
  --------------------------------------------------- -------------- -------------- ------------- ---- ----------
  Histological subtype                                S. Spreading   19 (67.9%)     9 (32.1%)     28   1.0
  L. Maligna                                          2 (100%)       0              2                  
  not informed                                        2 (100%)       0              2                  
  **[\*\*](#t002fn001){ref-type="table-fn"}Growth**   In situ        17 (94.4%)     1 (5.6%)      18   **0.03**
  Radial                                              3 (42.9%)      4 (57.1%)      7                  
  Vertical                                            3 (42.9%)      4 (57.1%)      7                  
  Ulceration                                          Absent         6 (42.9%)      8 (57.1%)     14   \+
  Clark                                               II             3 (42.9%)      4 (57.1%)     7    1.0
  III                                                 3 (42.9%)      4 (57.1%)      7                  
  Breslow                                             Mean (SD)      0.67 (0.23)    0.64 (0.25)        0.6
  Mitotic Index mm^2^                                 Mean (SD)      0.40 (0.92)    0.37 (0.89)        0.6
  Peritumoral Invasion                                Present        6 (46.2%)      7 (53.8%)     13   1.0
  Absent                                              0              1 (100%)       1                  
  Intratumoral Invasion                               Present        2 (28.6%)      5 (71.4%)     7    0.6
  Absent                                              4 (57.1%)      3 (42.9%)      7                  
  Regression                                          Absent         6 (42.9%)      8 (57.1%)     14   \+
  Lymphatic Invasion                                  Absent         6 (42.9%)      8 (57.1%)     14   \+
  Vascular Invasion                                   Absent         6 (42.9%)      8 (57.1%)     14   \+
  Perineural Invasion                                 Absent         6 (42.9%)      8 (57.1%)     14   \+
  Previous nevus                                      Present        6 (66.7%)      3 (33.3%)     9    0.7
  Absent                                              17 (73.9)      6 (26.1%)      23                 
  Microscopic Satelitosis                             Absent         6 (42.9%)      8 (57.1%)     14   \+
  Margins                                             Free           20 (69.0%)     9 (31.0%)     29   0.5
  Positive                                            3 (100%)       0              3                  

\*\*Fisher's Exact Test

a\. Negative: absence of staining

b\. Positive: any positive staining (focal or multifocal).

Superficial spreading melanoma was the most common histological subtype, comprising 87.5% (n = 28) of the cases and they were located on the torso (n = 11), limbs (n = 13) and head and neck (n = 4). Two cases were classified as lentigo maligna melanomas and they were located on the upper trunk and upper limb. In two cases the histological subtype could not be determined, since there was an overlapping of features (superficial spreading melanoma and lentigo maligna). Most melanomas were in situ (18/32; 56.3%) and were located on the head&neck (n = 1), torso (n = 9), upper limbs (n = 7) and lower limbs (n = 1). The invasive melanomas had a median Breslow thickness of 0.66mm and most had a Clark level between II and III. Peritumoral and intratumoral infiltrates were seen in 92.7% and 50% of melanomas, respectively. No ulceration, regression, satellitosis, perineural invasion, vascular invasion, nor lymphatic invasion was observed. Nine melanomas (9/32; 28.1%) were found to have an associated melanocytic nevus.

RCM analysis {#sec010}
------------

RCM images revealed that all 32 melanomas had an atypical honeycomb pattern, non-edged papillae and reticulated collagen. Other frequent features observed were atypical cobblestone (93.8%), sparse plump cells (90.4%), bright dots (62.5%), pagetoid cells (62.5%), edged papillae (62.5%), dermal-epidermal junction nests (59.4%) and sheet-like structures (53.1%). Most epidermal nests observed on RCM were of the dense variety. The distribution of RCM parameters is described further in [Table 3](#pone.0179745.t003){ref-type="table"}.

10.1371/journal.pone.0179745.t003

###### Confocal microscopy characteristics and *BRAF* V600E mutation.

![](pone.0179745.t003){#pone.0179745.t003g}

                                                                                  *BRAF* V600E                    
  ------------------------------------------------------------------ ------------ -------------- ----------- ---- ----------
  Atypical Honeycomb                                                 Present      23 (71.9%)     9 (28.1%)   32   \+
  Atypical Cobblestone                                               Present      22 (73.3%)     8 (26.7%)   30   0.5
  Absent                                                             1 (50.0%)    1 (50.0%)      2                
  Pagetoid cells                                                     Present      12 (60.0%)     8 (40.0%)   20   0.1
  Absent                                                             11 (91.7%)   1 (8.3%)       12               
  **[\*\*](#t003fn001){ref-type="table-fn"}Hyporreflective cells**   Present      3 (37.5%)      5 (62.5%)   8    **0.02**
  Absent                                                             20 (83.3%)   4 (16.7%)      24               
  **[\*\*](#t003fn001){ref-type="table-fn"}Epidermal nests**         Present      7 (50.0%)      7(50.0%)    14   **0.02**
  Absent                                                             16 (88.9%)   2 (11.1%)      18               
  **[\*\*](#t003fn001){ref-type="table-fn"}DEJ nests**               Present      11 (57.9%)     8 (42.1%)   19   **0.05**
  Absent                                                             12 (92.3%)   1 (7.7%)       13               
  **[\*\*](#t003fn001){ref-type="table-fn"}Edged papillae**          Present      17 (85.0%)     3 (15.0%)   20   **0.05**
  Absent                                                             6 (50.0%)    6 (50.0%)      12               
  Nonedged papillae                                                  Present      23 (71.9%)     9 (28.1%)   32   \+
  **[\*\*](#t003fn001){ref-type="table-fn"}Abscence of papillae**    Present      1 (25.0%)      3 (75.0%)   4    **0.06**
  Absent                                                             22 (78.6%)   6 (21.4%)      28               
  Sheet-like Structure                                               Present      12 (70.6%)     5 (29.4%)   17   1.0
  Absent                                                             11 (73.3%)   4 (26.7%)      15               
  **[\*\*](#t003fn001){ref-type="table-fn"}Meshwork**                Present      16 (88.9%)     2 (11.1%)   18   **0.02**
  Absent                                                             7 (50.0%)    7 (50.0%)      14               
  Mitochondria                                                       Present      4 (80.0%)      1 (20.0%)   5    1.0
  Absent                                                             19 (70.4%)   8 (29.6%)      27               
  Absent                                                             20 (69.0%)   9 (31.0%)      29               
  **[\*\*](#t003fn001){ref-type="table-fn"}Bright dots**             Present      17 (85.0%)     3 (15.0%)   20   **0.05**
  Absent                                                             6 (50.0%)    6 (50.0%)      12               
  Sparse Plump cells                                                 Present      22 (75.9%)     7 (24.1%)   29   0.2
  Absent                                                             1 (33.3%)    2 (66.7%)      3                
  Agregated Plump cells                                              Present      8 (72.7%)      3 (27.3%)   11   1.0
  Absent                                                             15 (71.4%)   6 (28.6%)      21               
  Reticulated Collagen                                               Present      23 (71.9%)     9 (28.1%)   32   \+
  Collagen Bundles                                                   Present      5 (83.3%)      1 (16.7%)   6    0.6
  Absent                                                             18 (69.2%)   8 (30.8%)      26               

\*\*Fisher's Exact Test

a\. Negative: absence of staining

b\. Positive: any positive staining (focal or multifocal).

*BRAF* analysis {#sec011}
---------------

Nine of 32 melanomas stained positive for the *BRAF* V600E mutation (28.1%; Figs [1](#pone.0179745.g001){ref-type="fig"} and [2](#pone.0179745.g002){ref-type="fig"}).

![Comparison between findings of dermatoscopy and RCM.\
(A) Dermoscopy of *BRAF* V600E negative *in situ* superficial spreading melanoma: broadened pigmented network (the inset corresponds to clinical image). (B) RCM mosaic image (1.5x1.5 mm) in DEJ shows junctional thickening due to isolated atypical cells (yellow arrows). (C) RCM mosaic image (1.5x1.5 mm) in DEJ showing non-edged papillae separated by loosely thick interpapillary spaces (yellow arrows) and meshwork pattern (red arrows). (D) Dermoscopy of *BRAF* V600E mutated superficial spreading melanoma, 1 mm in Breslow thickness): multicomponent pattern (the inset corresponds to clinical image). (E) RCM mosaic image (0.75x0.75 mm) at the level of the epidermis shows hyporeflective pagetoid cells (red arrows) and epidermal nests (yellow arrow). (F) RCM mosaic image (0.75x0.75 mm) at the level of the DEJ shows dermal-epidermal nests (yellow arrows).](pone.0179745.g002){#pone.0179745.g002}

Patients with *BRAF* positive melanomas were significantly younger (dichotomized into those ≤50 vs \>50 years of age) as compared to patients with *BRAF* wild type melanoma (p = 0.035) ([Fig 3](#pone.0179745.g003){ref-type="fig"}).

![Graphic age x *BRAF* V600E.](pone.0179745.g003){#pone.0179745.g003}

Melanomas that were *BRAF* mutated were more likely to be invasive (p = 0.03). No difference was observed in *BRAF* mutated vs *BRAF* wild type melanomas vis-a-vis patient gender, primary site of tumor, association with melanocytic nevus, nor any other histopathological parameter ([Table 2](#pone.0179745.t002){ref-type="table"}).

Differences in RCM parameters between *BRAF* mutated and wild type melanoma was observed. *BRAF* positive melanomas were more likely to reveal hyporreflective cells (p = 0.02; [Fig 2E](#pone.0179745.g002){ref-type="fig"}), epidermal nests (p = 0.02), dermal-epidermal junction nests (p = 0.05), edged papillae (p = 0.05), and bright dots (p = 0.05; [Table 3](#pone.0179745.t003){ref-type="table"}). In addition, *BRAF* mutated melanomas were less likely to reveal junctional thickening (p = 0.01) and a meshwork pattern (p = 0.02; [Table 4](#pone.0179745.t004){ref-type="table"}).

10.1371/journal.pone.0179745.t004

###### Clinical and histological characteristics of *BRAF* V600E mutated melanomas.

![](pone.0179745.t004){#pone.0179745.t004g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Case**   **Gender**   **Age**   **Local**       Histological\   Growth     Clark   Breslow   Mitotic index mm^2^   Peritumoral invasion[\*](#t004fn009){ref-type="table-fn"}   Intratumoral\                                   Pre-existing. Nevus[\*](#t004fn009){ref-type="table-fn"}   HRC (1)[\*](#t004fn009){ref-type="table-fn"}   EN (2)[\*](#t004fn009){ref-type="table-fn"}   DEJN (3)[\*](#t004fn009){ref-type="table-fn"}   EP (4)[\*](#t004fn009){ref-type="table-fn"}   AP (5)[\*](#t004fn009){ref-type="table-fn"}   N (6)[\*](#t004fn009){ref-type="table-fn"}   MS (7)[\*](#t004fn009){ref-type="table-fn"}   BD (8)[\*](#t004fn009){ref-type="table-fn"}
                                                    Type                                                                                                                           Invasion[\*](#t004fn009){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                  
  ---------- ------------ --------- --------------- --------------- ---------- ------- --------- --------------------- ----------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------------- ---------------------------------------------- --------------------------------------------- ----------------------------------------------- --------------------------------------------- --------------------------------------------- -------------------------------------------- --------------------------------------------- ---------------------------------------------
  1          Female       45        Upper limbs     SS              In situ                                                                                                                                                        0                                                          1                                              0                                             1                                               1                                             1                                             1                                            0                                             0

  2          Male         60        Upper limbs     SS              Radial     II      0.26      0                     0                                                           0                                               1                                                          0                                              0                                             0                                               0                                             0                                             1                                            1                                             1

  3          Female       47        Trunk           SS              Radial     III     0.79      1.25                  1                                                           0                                               1                                                          1                                              1                                             1                                               0                                             0                                             1                                            0                                             0

  4          Female       42        Head and neck   SS              Vertical   II      0.52      0                     1                                                           1                                               0                                                          1                                              1                                             1                                               0                                             1                                             1                                            0                                             0

  5          Male         61        Lower limbs     SS              Vertical   III     1         0                     1                                                           1                                               0                                                          1                                              1                                             1                                               0                                             0                                             0                                            0                                             0

  6          Female       28        Trunk           SS              Vertical   III     1         0                     1                                                           1                                               0                                                          0                                              1                                             1                                               0                                             1                                             0                                            0                                             0

  7          Female       62        Trunk           SS              Vertical   II      0.5       0                     1                                                           0                                               1                                                          0                                              1                                             1                                               1                                             0                                             1                                            0                                             0

  8          Male         47        Upper limbs     SS              Radial     III     0.71      0                     1                                                           1                                               0                                                          1                                              1                                             1                                               1                                             0                                             1                                            1                                             1

  9          Female       45        Upper limbs     SS              Radial     II      0.7       0                     1                                                           1                                               0                                                          0                                              1                                             1                                               0                                             0                                             1                                            0                                             1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^(1)^Hyporreflective cells

^(2)^Epidermal nests

^(3)^DEJ nests

^(4)^Edged papillae

^(5)^Abscence papillae

^(6)^Junctional thickening cell nests

^(7)^Meshwork

^(8)^Bright dots.

^**\***^0 means absence of parameter and 1 means presence of parameter.

SS: Superficial Spreading

Multiple logistic regression ([Table 5](#pone.0179745.t005){ref-type="table"}) identified the following independent RCM features predictive of *BRAF* V600E positivity: absence of meshwork pattern (OR = 14.3; 95%CI: 1.3--156.8) and absence of junctional thickening (OR = 16.7; 95% CI: 1.6--175.0).

10.1371/journal.pone.0179745.t005

###### Multivariate analysis for the identification of independent predictive factors for positive BRAF V600E.

![](pone.0179745.t005){#pone.0179745.t005g}

  Variable                                  n    OR     95%CI
  ----------------------------------------- ---- ------ ------------
  **Meshwork**                                          
  Absent                                    14   14.3   1.3--156.8
  Present                                   18   1.0    Reference
  **Junctional thickening cell agregate**               
  Absent                                    10   16.7   1.6--175.0
  Present                                   22   1.0    Reference

OR: Odds ratio

95%CI: 95% Confidence interval

Number of events: 9 (*BRAF* V600E +)

The distribution of cases as a function of *BRAF* status and the number of cumulative predictive factors for *BRAF* V600E positivity are depicted in [Table 6](#pone.0179745.t006){ref-type="table"}.

10.1371/journal.pone.0179745.t006

###### Distribution of cases according to BRAF V600E status and number of cumulative predictive factors.

![](pone.0179745.t006){#pone.0179745.t006g}

  ---------------------------------------------------------------
  Number of cumulative\     *BRAF* V600E                 
  predictive factors (\*)                                
  ------------------------- -------------- --------- --- --------
  None                      13             (100.0)   0   (0.0)

  One factor                9              (64.3)    5   (35.7)

  Two factors               1              (20.0)    4   (80.0)
  ---------------------------------------------------------------

Fisher's exact test: P = 0.002; Area under the curve (AUC): 0.86 (95%CI: 0.73--0.99).

(\*) Predictive factors: absence of meshwork and absence of junctional thickening cell agregate.

There was a statistically significant difference in *BRAF* positivity as a function of the number of cumulative factors (p = 0.002) present, ranging from zero up to 80%. This model had an AUC equal to 0.86 (95% CI: 0.73--0.99), as depicted in [Fig 4](#pone.0179745.g004){ref-type="fig"}.

![ROC curve of positivity for *BRAF* V600E.](pone.0179745.g004){#pone.0179745.g004}

Discussion {#sec012}
==========

The discovery that melanomas could be sub-classified based on their mutation profile provided the basis for the molecular classification of cutaneous melanoma \[[@pone.0179745.ref015]\]. While many mutations have been identified in melanoma, the most common is the *BRAF* V600E mutation, which is seen in approximately 50% of cutaneous melanomas \[[@pone.0179745.ref009],[@pone.0179745.ref016],[@pone.0179745.ref017]\] Studies have shown that *BRAF* mutated melanomas tend to develop in younger individuals as compared to *BRAF* wild type melanomas \[[@pone.0179745.ref018],[@pone.0179745.ref002]\]. Indeed, 66.7% (6 of 9) of the patients with *BRAF*-mutated melanomas in our cohort were younger than 50 years of age. In contrast, 86.9% of the patients with *BRAF wild type* melanomas were older than 50; similar observations were also made by Menzies et al. \[[@pone.0179745.ref018]\]. Approximately one third of the *BRAF* mutated melanomas in our cohort were found to have an associated nevus in the histologic examination. Similar observations were made by Shitara et al. \[[@pone.0179745.ref019]\], who noted that 38.3% (23/60) of their V600E-mutated melanomas had an associated nevus that was also V600E-mutated.

RCM enables clinicians to visualize subsurface skin structures on the cellular level *in vivo*. The features seen on RCM correlate well with features seen on routine histological examination \[[@pone.0179745.ref020],[@pone.0179745.ref021],[@pone.0179745.ref022]\]. One previous study evaluated six *BRAF* V600E mutated primary melanomas and 2 metastasis \[[@pone.0179745.ref007]\] with RCM and found them to reveal pleomorphic pagetoid cells, disarrangement of the dermal-epidermal junction, discohesive junctional nests and bright particles at the DEJ. In our cohort, the presence of bright dots, which correlates with inflammation (leukocyte infiltration), was the only parameter found in common with Ruini et al.'s study being significantly associated with *BRAF* V600E status.

Since the presence of both bright dendritic and roundish cells in the spinous layer correlate with the presence of pagetoid cells on histopathology \[[@pone.0179745.ref023]\], we elected not to differentiate between these two subtypes of pagetoid cells seen on RCM~~.~~ While Viros et al. observed on histopathology that increased upward scatter of intraepidermal melanocytes was associated with *BRAF* mutations \[[@pone.0179745.ref024]\], we did not find the same on RCM imaging. However, we did find that the presence of 'hyporeflective pagetoid cells' (HPCs), described as round dark structures (similar to 'holes') within the epidermis \[[@pone.0179745.ref025]\], was significantly correlated with *BRAF* V600E mutation. Of interest, these hyporeflective cells have been described in hypomelanotic melanomas, Paget\'s disease \[[@pone.0179745.ref026]\], and rarely in pigmented melanomas \[[@pone.0179745.ref024]\].

One of the novel findings of our study was that not only the presence of dermal-epidermal nest but also the presence of intraepidermal nests are associated with *BRAF* V600E mutations. This finding is consistent with Viros et al.'s histopathology study showing that intraepidermal melanocytes arranged in nests were positively associated with *BRAF*-mutation status \[[@pone.0179745.ref024]\]. Since *BRAF* V600E mutations are commonly seen in dermal nevi, it is tempting to speculate whether *BRAF* mutations can directly lead to nest formation \[[@pone.0179745.ref027],[@pone.0179745.ref028],[@pone.0179745.ref006]\]. It is interesting to note that while many melanomas reveal sparse nests, the nests in our *BRAF* mutated melanomas were dense; similar to nests seen in intradermal nevi, most of which also happen to harbor *BRAF* V600E mutations \[[@pone.0179745.ref029]\], No cerebriform nests were observed, most probably because the melanomas in our cohort were thin tumors.

Recently an attempt has been made to group melanomas based on their RCM features. Four types of melanomas have been identified: dendritic cell melanomas, round cell melanomas, dermal nest melanomas, and combined type melanomas. Melanomas with a meshwork pattern have been associated with both dendritic and round cell melanomas \[[@pone.0179745.ref030]\]. While dendritic cell melanomas were associated with the presence of thin meshwork pattern and dendritic cells, round cell melanomas were associated with the presence of large round cells distributed in a pagetoid fashion and with nest formation. This latter type melanoma was found to be associated with *BRAF* V600E mutations. Patients with this type of melanoma tend to be younger, have multiple nevi and rarely develop melanoma on chronic sun exposed skin. In contrast, dendritic cell melanomas tend to reveal junctional thickening resulting from isolated atypical cells without nest formation. These melanomas tend to be *BRAF* wild type \[[@pone.0179745.ref030]\]. Indeed, after multivariate analysis, the most important predictive factors for *BRAF* V600E positivity were the absence of meshwork and/or absence of junctional thickening. In other words, if both parameters are absent there is a high likelihood that the melanoma will harbor the *BRAF* V600E mutation.

The findings of the present study reveals that *BRAF* V600E mutated melanomas tend to have epidermal and DEJ nests, are of the superficial spreading type, occur at a younger age, and are located on intermittently sun exposed areas. In contrast, *BRAF wild type* melanomas develop at an older age, reveal a thin meshwork pattern and junctional thickening. The aforementioned supports the existence of different pathways to melanomas, leading to different subsets of melanomas, each depicting particular clinical, dermoscopic and RCM features ([Table 7](#pone.0179745.t007){ref-type="table"}).

10.1371/journal.pone.0179745.t007

###### Clinical, dermoscopic, confocal microscopy and histopathological features of positive and negative BRAF V600E melanomas.

![](pone.0179745.t007){#pone.0179745.t007g}

  *BRAF* V600E   Clinic                     Dermoscopy                                                                                                     Confocal microscopy                                                                                              Histopathology
  -------------- -------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  POSITIVE       Age \< 50 (*p* = 0,022);   Globular pattern with irregular globules; Blotches                                                             Hyporeflective cells in epidermis (*p* = 0,21); Epidermal nests (*p* = 0,019); Junctional nests (*p* = 0,035);   Radial growth (*p* = 0,003); Vertical growth (*p* = 0,003)
  NEGATIVE       Age \> 50 (*p* = 0,022);   Atypical network; Sparse irregular globules; Radial projections; Irregular hypopigmentation; Veil; Peppering   Edged papillae (*p* = 0,038); Junctional thickening cell aggregates (*p* = 0,012); Meshwork (*p* = 0,019);       *In situ* (*p* = 0,003)

Melanomas occurring at a younger age, on intermittently sun-exposed areas, with tendency to nest formation are clearly different from melanomas in older patients, on chronically sun exposed areas, with histopathological tendency of more lentiginous proliferation.

The present study highlights the potential of RCM to be used as a supplementary tool in the screening for *BRAF-*mutated melanomas. The findings of the presence of intraepidermal nests, DEJ nest, bright dots, in the absence of junctional thickening and absence of meshwork is highly suggestive that the melanoma in question will harbor a *BRAF* V600E mutation.
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